

PROBLEM

Chronic non-healing wounds and excessive scar formation are two of the biggest challenges in wound healing. Effective drugs to address these challenges don't exist yet. The outcome of therapies are not satisfactory and worldwide annual costs exceed \$24 B.

Insufficient ocular blood flow in several eye diseases leads to damaging the eye nerve and ultimately to blindness. This high medical need indications represent currently an \$11 B market with an attractive annual growth of 8%.

SOLUTION

TOP-N53 our priority development drug increases local blood flow in the wound area and addresses the impaired blood flow, a central problem in non-healing wounds. TOP-N53 has a unique mode of action and an unprecedented efficacy to enable wound healing.

TOP-N44 inhibits excessive scar formation, targeting a huge medical need after burn wounds.

TOP-N73a increases ocular blood flow and has the potential to become a breakthrough drug preventing blindness.

Wound healing
TOP-N53



Scar & keloid prevention
TOP-N44



Ocular blood flow
TOP-N73a



Out licensing
TOP-N73b-d



COMPANY

After six years of intensive lead finding phase Dr. Reto Naef, together with an experienced pharma team, founded TOPADUR Pharma AG in March 2015. The leadership and board members have more than 150 years of successful pharma experience. The development pipeline is supported by strong IP. The invention of new mode of action drugs resulted also in an attractive out-licensing portfolio outside wound healing indications.

The company has 15 employees, seven major collaborations with leading research groups in Europe and four international CROs.

PRODUCT PORTFOLIO

- TOP-N53 Diabetic foot ulcer wound healing, rare w.h. indications
- TOP-N44 Prevention of excessive scar formation
- TOP-N73a Glaucoma and ophthalmic indications
- TOP-N73b Erectile dysfunction (topical) out-licensing
- TOP-N73c Pulmonary arterial hypertension (inhaled) out-licensing
- TOP-N73d Medical cosmetics out-licensing

GROWTH STRATEGY

TOPADUR is developing TOP-N53, TOP-N44 and TOP-N73a to clinical phase 2a and will be partnering with big pharma companies afterwards. In rare disease indications the company intends to bring the product to the market without partnering. TOPADUR has ongoing research projects in several indications with disturbed microcirculation.

FINANCIALS

- \$0.3 M seed round by founder 2009-2015
- \$2.2 M Series A Q1/2016
- \$6.2 M Series B Q2/2017
- \$4.5 M convertible loan Q3/2018
- Non-diluting funding \$2.6 M
- submitted grant applications \$2.5M
- **next: Series C: \$8-10 M mid 2019**
- **expected exit: 2021/22**

NEXT MILESTONES

- TOP-N53 end toxicology Q2/18
- IND Q3/18
- FIH Q1/19

IND: investigational new drug; FIH: first in human; POC: proof of concept

AWARDS

- Winners Pitching Battle CEO day 2015
- Finalist Swiss Innovation Challenge 2015
- Winner Venture Leaders Life Science 2016
- Top 100 Swiss Startups 2016
- CTI label company 2016
- Winner IMD Startup 2016
- Top 100 Swiss Startups 2017
- Winner Swiss Innovation Challenge 2017
- Winner Venture Leaders China 2018
- Top 100 Swiss Startups 2018
- Winner SEF Award 2018
- Winner ED Dong Sheng Cup 2018

TOPADUR Pharma AG
Grabenstrasse 11A
CH-8952 Schlieren
T +41 44 755 44 66
M + 41 79 204 77 05

info@topadur.com
www.TOPADUR.com